tradingkey.logo

Rapid Micro Biosystems Inc

RPID
查看詳細走勢圖
3.200USD
+0.050+1.59%
交易中 美東報價延遲15分鐘
141.79M總市值
虧損本益比TTM

Rapid Micro Biosystems Inc

3.200
+0.050+1.59%
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

+1.59%

5天

-12.09%

1月

-23.26%

6月

-3.61%

今年開始到現在

+255.56%

1年

+255.56%

查看詳細走勢圖

TradingKey Rapid Micro Biosystems Inc股票評分

單位: USD 更新時間: 2025-12-19

操作建議

Rapid Micro Biosystems Inc當前公司基本面數據相對健康,增長潛力較大。當前估值合理,在醫療設備與耗材行業排名117/208位。機構持股佔比非常高,近一個月多位分析師給出公司評級為買入。最高目標價8.00。中期看,股價處於平穩狀態。近一個月,市場表現非常差,但技術面評分較高。目前股價在壓力位和支撐位之間,可以做區間波段操作。

Rapid Micro Biosystems Inc評分

相關信息

行業排名
117 / 208
全市場排名
278 / 4582
所屬行業
醫療設備與耗材

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

分析師目標

基於 4 分析師
買入
評級
8.000
目標均價
+101.01%
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議

Rapid Micro Biosystems Inc亮點

亮點風險
Rapid Micro Biosystems, Inc. is a life sciences technology company providing mission-critical automation solutions to facilitate the manufacturing and release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. Its flagship Growth Direct system automates and modernizes the antiquated, manual microbial quality control (MQC) testing workflows used in pharmaceutical manufacturing operations. It offers four specific applications for testing of microbial contamination: Environmental Monitoring, which tests the manufacturing environment, including circulating air, exposed surfaces, and personnel; Water, which tests any purified water used at any stage of the drug production process, including water for injection; In-Process Bioburden, which tests raw materials, drug substance and in-process product, and Sterility Release offering final testing of finished product to ensure sterility before the product is released for commercial sale.
業績高增長
公司營業收入穩步增長,連續3年增長63.72%
業績增長期
公司處於發展階段,最新年度總收入28.05M美元
估值低估
公司最新PE估值-3.16,處於3年歷史低位
機構減倉
最新機構持股23.72M股,環比減少6.05%
先鋒集團持倉
明星投資者先鋒集團持倉,最新持倉965.02K股

Rapid Micro Biosystems Inc新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

Rapid Micro Biosystems Inc簡介

Rapid Micro Biosystems, Inc. is a life sciences technology company providing mission-critical automation solutions to facilitate the manufacturing and release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. Its flagship Growth Direct system automates and modernizes the antiquated, manual microbial quality control (MQC) testing workflows used in pharmaceutical manufacturing operations. It offers four specific applications for testing of microbial contamination: Environmental Monitoring, which tests the manufacturing environment, including circulating air, exposed surfaces, and personnel; Water, which tests any purified water used at any stage of the drug production process, including water for injection; In-Process Bioburden, which tests raw materials, drug substance and in-process product, and Sterility Release offering final testing of finished product to ensure sterility before the product is released for commercial sale.
公司代碼RPID
公司Rapid Micro Biosystems Inc
CEOSpignesi (Robert)
網址https://www.rapidmicrobio.com/

常見問題

Rapid Micro Biosystems Inc(RPID)的當前股價是多少?

Rapid Micro Biosystems Inc(RPID)的當前股價是 3.200。

Rapid Micro Biosystems Inc 的股票代碼是什麼?

Rapid Micro Biosystems Inc的股票代碼是RPID。

Rapid Micro Biosystems Inc股票的52週最高點是多少?

Rapid Micro Biosystems Inc股票的52週最高點是4.500。

Rapid Micro Biosystems Inc股票的52週最低點是多少?

Rapid Micro Biosystems Inc股票的52週最低點是0.870。

Rapid Micro Biosystems Inc的市值是多少?

Rapid Micro Biosystems Inc的市值是141.79M。

Rapid Micro Biosystems Inc的淨利潤是多少?

Rapid Micro Biosystems Inc的淨利潤為-46.89M。

現在Rapid Micro Biosystems Inc(RPID)的股票是買入、持有還是賣出?

根據分析師評級,Rapid Micro Biosystems Inc(RPID)的總體評級為買入,目標價格為8.000。

Rapid Micro Biosystems Inc(RPID)股票的每股收益(EPS TTM)是多少

Rapid Micro Biosystems Inc(RPID)股票的每股收益(EPS TTM)是-0.998。
KeyAI